Clinical trial

Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy.

NCT03889236

Study summary

ClinicalTrials.gov

Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy.

Design: INTERVENTIONAL · Status: COMPLETED · Phase: NA

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

OTHER · Unmapped registry intervention Fasting mimicking diet Prolon Find medicine records · Find other trials using this name

DIETARY_SUPPLEMENT · Unmapped registry intervention Food supplement Endocalyx Find medicine records · Find other trials using this name

DIETARY_SUPPLEMENT · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-05-03

PhaseNA

Conditions

Diabetic Nephropathy Type 2unresolved

Albuminuriaunresolved

Type2 Diabetes Mellitusunresolved

Glucose Metabolism Disordersunresolved

Microalbuminuriaunresolved

Diabetic Nephropathiesunresolved

Diabetic Complications Renalunresolved

Diabetes Mellitusverified · MONDO: diabetes mellitus

Kidney Diseasesunresolved

South Asianunresolved

Interventions

Fasting mimicking diet ProlonOTHER

Food supplement EndocalyxDIETARY_SUPPLEMENT

PlaceboDIETARY_SUPPLEMENT

Sponsors & collaborators

Leiden University Medical Centerlead sponsor

Dutch Kidney Foundationcollaborator

Health Hollandcollaborator

Radboud University Medical Centercollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03889236 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.